Neutrophil Integrins in Defense against Drug-Resistant C. albicans

中性粒细胞整合素防御耐药白色念珠菌

• 批准号: 10216507
• 负责人: Brian William LeBlanc
• 金额: $ 24.43万
• 依托单位: MIRIAM HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-01 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10216507
• 关键词: Antibiotic Resistance; Antibiotics; Antimicrobial Resistance; Bacterial Antibiotic Resistance; Biomedical Research; Biotechnology; Candida albicans; Centers of Research Excellence; Cessation of life; Chemotherapy-Oncologic Procedure; Clinical; Clinical Medicine; Communicable Diseases; Communities; Core Facility; Dedications; Discipline; Drug resistance; Ensure; Environment; Faculty; Financial Hardship; Fostering; Funding; Generations; Goals; Healthcare; Hospital Costs; Hospitals; Infection; Infrastructure; Institution; Integrins; International; Intervention; Investments; Laboratories; Laboratory Research; Longevity; Medical; Mentors; Organ Transplantation; Participant; Pharmaceutical Preparations; Pharmacologic Substance; Phase; Pilot Projects; Primary Health Care; Program Development; Research; Research Personnel; Resistance; Resort; Resources; Rhode Island; Services; Therapeutic; Training Support; United States; Universities; Work; antimicrobial drug; career; career development; clinical practice; cost; design; drug discovery; drug resistant pathogen; innovation; microorganism; multidisciplinary; neutrophil; novel strategies; novel therapeutic intervention; novel therapeutics; programs; resistance mechanism; success

Resistance to antimicrobial therapies is a national and international crisis that threatens clinical practice from fundamental primary care to the most advanced medical interventions such as cancer chemotherapy and organ transplantation. Much of what we take for granted in clinical medicine could become too risky as microorganisms have become increasingly resistant to our newest medications and our antibiotics of last resort. Antimicrobial resistance also adds enormous costs to health care, exceeding $21 billion in the United States alone. Compounding this problem is the fact that pharmaceutical companies have largely abandoned antibiotic development programs. As an alternative to large pharmaceutical companies, academic institutions and biotech startups can step in to refill the antibiotic pipeline using novel approaches to drug discovery. The principal objective of this Phase I COBRE application is to build a unique, multi-disciplinary center of excellence to study mechanisms of antimicrobial resistance and develop therapeutic countermeasures. The long-term goal of the Center for Antimicrobial Resistance and Therapeutic Discovery (CARTD) at The Miriam Hospital of the Lifespan Hospital Group is to develop new therapies for infections caused by drug resistant pathogens. This long-term goal will be attained with shorter-term objectives of developing a new generation of junior investigators who study mechanisms of resistance, characterize new targets, and study new and existing compounds. CARTD will integrate their work with mentors and established investigators at the institution and develop core facilities to enhance research capabilities in the field of antimicrobial resistance and the discovery of new therapeutics. To achieve these objectives, the CARTD will complete the following specific aims: 1. Consolidate existing researchers into a dynamic, interactive center of excellence across The Miriam Hospital, and its academic partners in Rhode Island, including Brown University. 2. Foster the research programs and career development of junior investigators in the field of antimicrobial resistance and studies of novel therapeutic approaches. 3. Support new institutional research with pilot project funding. 4. Establish critical infrastructure with new core laboratories to facilitate cutting edge research in antimicrobial resistance and therapeutic discovery, and serve as a unique technical resources to other COBRE research programs, other institutional researchers, and investigators in the region.

对抗菌药物的耐药性是一种国家和国际危机，威胁着临床实践 基本初级保健到最先进的医疗干预措施，如癌症化疗和 器官移植。我们在临床医学中认为理所当然的许多东西可能会变得过于危险，因为 微生物对我们最新的药物和过去的抗生素产生了越来越强的抗药性 度假村。抗菌素耐药性也增加了医疗保健的巨大成本，在美国超过210亿美元 只有一个州。使这个问题变得更加复杂的是，制药公司基本上已经放弃了 抗生素开发计划。作为大型制药公司、学术机构的替代方案 生物技术初创公司可以介入，使用新的药物发现方法来补充抗生素管道。这个 第一阶段Cobre应用的主要目标是建立一个独特的、多学科的 擅长研究抗菌素耐药机制和制定治疗对策。这个 Miriam抗菌素耐药性和治疗发现中心(CARTD)的长期目标 长寿医院集团旗下医院将开发治疗耐药感染的新疗法 病原体。这一长期目标将通过开发新一代网络的短期目标来实现 初级研究人员，研究抗性机制，确定新目标的特征，并研究新的和现有的 化合物。CARTD将把他们的工作与该机构的导师和资深调查人员结合起来，并 发展核心设施，以加强在抗菌素耐药性和发现领域的研究能力 新的治疗方法。为实现这些目标，亚太区域研究开发中心将完成以下具体目标：1. 将现有的研究人员整合到整个Miriam医院的一个动态、互动的卓越中心， 以及它在罗德岛的学术合作伙伴，包括布朗大学。2.促进研究计划和 抗菌药物耐药和新药研究领域初级研究人员的职业发展 治疗方法。3.以试点项目资金支持新的机构研究。4.建立关键 拥有新的核心实验室的基础设施，以促进抗菌素耐药性和 治疗发现，并作为其他Cobre研究计划的独特技术资源，其他 机构研究人员和该地区的调查人员。